(Q41104059)

26 September 2017

1 reference

title

A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy (English)

1 reference

26 September 2017

0 references

1 reference

D Hughes

1

1 reference

26 September 2017

O C Cockerell

series ordinal

2

1 reference

26 September 2017

publication date

1 June 1996

1 reference

Seizure-European Journal of Epilepsy

26 September 2017

published in

1 reference

26 September 2017

volume

5

1 reference

26 September 2017

issue

2

1 reference

26 September 2017

page(s)

89-95

1 reference

Epileptic seizures in a population of 6000. I: Demography, diagnosis and classification, and role of the hospital services.

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Epilepsy in a population of 6000 re-examined: secular trends in first attendance rates, prevalence, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Outcomes of add-on treatment with lamotrigine in partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

1 reference

7 January 2021

Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Place of newer antiepileptic drugs in the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Lessons for neurologists from the United Kingdom Third National Morbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

The nature of epilepsy in the general population. II. Medical care

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Open, double-blind and long-term study of vigabatrin in chronic epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Safety of lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

The cost of epilepsy in patients attending a specialist epilepsy service

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Pharmacokinetic optimisation of anticonvulsant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Newer antiepileptic drugs. Towards an improved risk-benefit ratio

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Audit of the management of patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Economic evaluation and health care. What does it mean?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Cost effectiveness of magnetic resonance imaging in the neurosciences

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

Costing Consultations in General practice: Towards a Standardized Method

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2896%2980100-2

7 January 2021

10.1016/S1059-1311(96)80100-2

Identifiers

DOI

1 reference

26 September 2017

1 reference